Results 11 to 20 of about 1,972,453 (318)

Deep learning method for prediction of patient-specific dose distribution in breast cancer

Radiation Oncology, 2021
Background Patient-specific dose prediction improves the efficiency and quality of radiation treatment planning and reduces the time required to find the optimal plan. In this study, a patient-specific dose prediction model was developed for a left-sided
Sang Hee Ahn, EunSook Kim, Chankyu Kim, Wonjoong Cheon, Myeongsoo Kim, Se Byeong Lee, Young Kyung Lim, Haksoo Kim, Dongho Shin, Dae Yong Kim, Jong Hwi Jeong   +10 more
doaj   +1 more source

Autophagy and cancer therapy [PDF]

Cancer Biology & Therapy, 2011
Although autophagy has been shown to have a clear role as a tumor suppressor mechanism, its role in cancer treatment is still controversial. Because autophagy is a survival pathway activated during nutrient deprivation and other stresses, it is reasonable to think that autophagy can function as a tumor cell survival mechanism activated after cancer ...
Paola, Maycotte, Andrew, Thorburn
openaire   +2 more sources

A hard pill to swallow: a qualitative study of women’s experiences of adjuvant endocrine therapy for breast cancer [PDF]

, 2014
Objective: To explore women’s experiences of taking adjuvant endocrine therapy as a treatment for breast cancer and how their beliefs about the purpose of the medication, side effects experienced and interactions with health professionals might influence
McCowan, Colin, Harrow, Alison, Thompson, Alastair M., McCowan, C, Radley, Andrew, Wells, Mary, Radley, Andrew; id_orcid, Parsons, Mark, Dryden, R, Dryden, Ruth, Thompson, Alastair M, Parsons, M, Wells, M, Thompson, Alastair, Radley, A, Thompson, AM, Harrow, A   +16 more
core   +1 more source

Long-term results of a phase II study of hypofractionated proton therapy for prostate cancer: moderate versus extreme hypofractionation

Radiation Oncology, 2019
Background We performed a prospective phase II study to compare acute toxicity among five different hypofractionated schedules using proton therapy. This study was an exploratory analysis to investigate the secondary end-point of biochemical failure-free
Boram Ha, Kwan Ho Cho, Kang Hyun Lee, Jae Young Joung, Yeon-Joo Kim, Sung Uk Lee, Hyunjung Kim, Yang-Gun Suh, Sung Ho Moon, Young Kyung Lim, Jong Hwi Jeong, Haksoo Kim, Weon Seo Park, Sun Ho Kim   +13 more
doaj   +1 more source

The use of hyperbaric oxygen to treat actinic rectal fistula after SpaceOAR use and radiotherapy for prostate cancer: a case report

BMC Urology, 2020
Background In definitive radiation therapy for prostate cancer, the SpaceOAR® System, a hydrogel spacer, is widely used to decrease the irradiated dose and toxicity of rectum.
Tairo Kashihara, Koji Inaba, Motokiyo Komiyama, Hiroki Nakayama, Kotaro Iijima, Shie Nishioka, Hiroyuki Okamoto, Nao Kikkawa, Yuko Kubo, Satoshi Shima, Satoshi Nakamura, Ayaka Takahashi, Kana Takahashi, Kae Okuma, Naoya Murakami, Hiroshi Igaki, Yuko Nakayama, Arinobu Fukunaga, Yoshiyuki Matsui, Hiroyuki Fujimoto, Jun Itami   +20 more
doaj   +1 more source

Online adaptive radiotherapy for bladder cancer using a simultaneous integrated boost and fiducial markers

Radiation Oncology, 2023
Purpose The aim was to assess the feasibility of online adaptive radiotherapy (oART) for bladder cancer using a focal boost by focusing on the quality of the online treatment plan and automatic target delineation, duration of the workflow and performance
Sana Azzarouali, Karin Goudschaal, Jorrit Visser, Maarten Hulshof, Marjan Admiraal, Niek van Wieringen, Jakko Nieuwenhuijzen, Jan Wiersma, Laurien Daniëls, Duncan den Boer, Arjan Bel   +10 more
doaj   +1 more source

Frequent adaptive immune responses against arginase-1

OncoImmunology, 2018
The enzyme arginase-1 reduces the availability of arginine to tumor-infiltrating immune cells, thus reducing T-cell functionality in the tumor milieu. Arginase-1 is expressed by some cancer cells and by immune inhibitory cells, such as myeloid-derived ...
Evelina Martinenaite, Rasmus Erik Johansson Mortensen, Morten Hansen, Morten Orebo Holmström, Shamaila Munir Ahmad, Nicolai Grønne Dahlager Jørgensen, Özcan Met, Marco Donia, Inge Marie Svane, Mads Hald Andersen   +9 more
doaj   +1 more source

An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma

OncoImmunology, 2021
Cells in the tumor microenvironment of Follicular lymphoma (FL) express checkpoint molecules such as programmed death ligands 1 and 2 (PD-L1 and PD-L2) and are suppressing anti-tumor immune activity.
Uffe Klausen, Nicolai Grønne Dahlager Jørgensen, Jacob Handlos Grauslund, Shamaila Munir Ahmad, Anne Ortved Gang, Evelina Martinenaite, Stine Emilie Weis-Banke, Marie Fredslund Breinholt, Guy Wayne Novotny, Julie Westerlin Kjeldsen, Morten Orebo Holmström, Lone Bredo Pedersen, Christian Bjørn Poulsen, Per Boye Hansen, Özcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Møller Pedersen, Mads Hald Andersen   +18 more
doaj   +1 more source

Targeting in Cancer Therapies [PDF]

Medical Sciences, 2016
Drug developers recruit and combine principles, procedures and strategies from chemistry, pharmacology, nanotechnology and biotechnology, focusing on the generation of functional vehicles as nano-carriers of drugs for improved stability and enhanced intracellular delivery.[...]
Ramon Mangues, Esther Vázquez, Antonio Villaverde   +2 more
openaire   +4 more sources

Particle Therapy for Breast Cancer

, 2022
Particle therapy has received increasing attention in the treatment of breast cancer due to its unique physical properties that may enhance patient quality of life and reduce the late effects of therapy.
Roman O. Kowalchuk, Kimberly S. Corbin, Rachel B. Jimenez   +2 more
core   +1 more source